A phase 1 trial shows that a dual-target CAR T-cell therapy called AZD0120 is highly effective and safe for older adults with newly diagnosed multiple myeloma, including frail patients.
The study included patients with a median age of 72 and found extremely strong early results. All patients achieved a complete response and no detectable cancer at a very sensitive level within one month. After nearly 10 months of follow-up, none of the patients had disease progression or died.
AZD0120 works by targeting two proteins, BCMA and CD19, instead of just one, helping it attack cancer cells more effectively. Despite concerns about safety in older patients, side effects were mild, with no severe neurological complications and only short-lived low-grade inflammatory reactions.
Researchers also used a faster “next-day” manufacturing process to prepare the CAR T cells, reducing waiting time for treatment. Overall, the results suggest this therapy could offer a powerful and well-tolerated option for older patients who often cannot handle intensive chemotherapy.